Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)
South Korea · Delayed Price · Currency is KRW 3,905.00
-70.00 (-1.76%)
At close: Feb 13, 2026
Korea Arlico Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 205,210 | 190,436 | 187,155 | 167,737 | 140,157 | 124,809 |
Other Revenue | -0 | - | - | - | -0 | 0 |
| 205,210 | 190,436 | 187,155 | 167,737 | 140,157 | 124,809 | |
Revenue Growth (YoY) | 12.41% | 1.75% | 11.58% | 19.68% | 12.30% | 7.79% |
Cost of Revenue | 99,305 | 90,708 | 77,038 | 60,871 | 52,672 | 45,134 |
Gross Profit | 105,905 | 99,728 | 110,116 | 106,866 | 87,485 | 79,674 |
Selling, General & Admin | 96,868 | 97,378 | 101,455 | 89,043 | 73,629 | 65,039 |
Research & Development | 5,524 | 4,539 | 4,180 | 6,532 | 8,194 | 3,142 |
Amortization of Goodwill & Intangibles | 108.61 | 91.49 | 79.97 | 82.7 | 81.82 | 54.83 |
Other Operating Expenses | 242.53 | 354.96 | 211.67 | 285.4 | 180.17 | 389.1 |
Operating Expenses | 103,870 | 104,887 | 107,044 | 97,002 | 82,691 | 69,075 |
Operating Income | 2,034 | -5,159 | 3,073 | 9,864 | 4,794 | 10,599 |
Interest Expense | -2,105 | -2,105 | -1,587 | -968.39 | -276.95 | -639.09 |
Interest & Investment Income | 338.53 | 338.53 | 435.17 | 518.13 | 167.72 | 361.15 |
Currency Exchange Gain (Loss) | 236.79 | 236.79 | 36.71 | 141.57 | 138.03 | -74.76 |
Other Non Operating Income (Expenses) | -2,476 | -192 | 1,319 | -1,019 | -213.08 | -344.92 |
EBT Excluding Unusual Items | -1,971 | -6,881 | 3,276 | 8,536 | 4,610 | 9,902 |
Gain (Loss) on Sale of Investments | 240.36 | 240.36 | 190.04 | 168.93 | 30.37 | 24.67 |
Gain (Loss) on Sale of Assets | 392.92 | 392.92 | 9.08 | -313.88 | 964.68 | -198.54 |
Other Unusual Items | 73.26 | 73.26 | - | - | - | - |
Pretax Income | -1,265 | -6,174 | 3,476 | 8,391 | 5,605 | 9,728 |
Income Tax Expense | 105.89 | -816.11 | 414.67 | 356.96 | 675.18 | 1,356 |
Net Income | -1,371 | -5,358 | 3,061 | 8,034 | 4,930 | 8,372 |
Net Income to Common | -1,371 | -5,358 | 3,061 | 8,034 | 4,930 | 8,372 |
Net Income Growth | - | - | -61.90% | 62.98% | -41.12% | -16.54% |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 29 | 15 | 15 | 15 |
Shares Change (YoY) | -0.14% | -48.99% | 94.89% | 0.18% | -0.06% | 51.13% |
EPS (Basic) | -91.41 | -356.88 | 204.00 | 535.00 | 327.00 | 555.00 |
EPS (Diluted) | -91.41 | -356.88 | 104.00 | 532.00 | 327.00 | 555.00 |
EPS Growth | - | - | -80.45% | 62.69% | -41.08% | -44.78% |
Free Cash Flow | -472.28 | -12,085 | -16,237 | -14,137 | 3,699 | -4,843 |
Free Cash Flow Per Share | -31.50 | -804.92 | -551.67 | -936.13 | 245.38 | -321.05 |
Gross Margin | 51.61% | 52.37% | 58.84% | 63.71% | 62.42% | 63.84% |
Operating Margin | 0.99% | -2.71% | 1.64% | 5.88% | 3.42% | 8.49% |
Profit Margin | -0.67% | -2.81% | 1.64% | 4.79% | 3.52% | 6.71% |
Free Cash Flow Margin | -0.23% | -6.35% | -8.68% | -8.43% | 2.64% | -3.88% |
EBITDA | 7,389 | 1,456 | 7,844 | 12,977 | 7,400 | 12,629 |
EBITDA Margin | 3.60% | 0.77% | 4.19% | 7.74% | 5.28% | 10.12% |
D&A For EBITDA | 5,355 | 6,615 | 4,772 | 3,113 | 2,606 | 2,030 |
EBIT | 2,034 | -5,159 | 3,073 | 9,864 | 4,794 | 10,599 |
EBIT Margin | 0.99% | -2.71% | 1.64% | 5.88% | 3.42% | 8.49% |
Effective Tax Rate | - | - | 11.93% | 4.25% | 12.05% | 13.94% |
Advertising Expenses | - | 1,096 | 890.82 | 294.4 | 590.9 | 141.32 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.